<DOC>
	<DOCNO>NCT01073462</DOCNO>
	<brief_summary>The purpose study ascertain percentage cardiac patient chronic kidney disease ( CKD ) stage 5 treat paricalcitol IV achieve intact parathyroid hormone ( iPTH ) level target range Kidney Disease Outcomes Quality Initiative ( K/DOQI ) treatment guideline ( 150 - 300 pg/mL ) 2 year .</brief_summary>
	<brief_title>Study Evaluate Effect Intravenous ( IV ) Paricalcitol ( Zemplar ) Cardiac Morbidity Patients With Chronic Kidney Disease ( CKD ) Stage 5 Over 2 Years</brief_title>
	<detailed_description>Secondary hyperparathyroidism ( SHPT ) frequent complication patient chronic kidney disease ( CKD ) stage 5 receive dialysis . SHPT adaptive response CKD characterize elevation parathyroid hormone ( PTH ) consecutively high calcium level . Elevations calcium level , phosphate level , PTH correlate CKD disease progression well development aggravation cardiovascular impairment . Many CKD patient treat well Vitamin D analogues effect calcium . Hypercalcemia well - know factor cardiac disease . No data available Austria cohort cardiac disease treat Zemplar ( paricalcitol IV ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients age least 18 year Patients secondary hyperparathyroidism associate CKD stage 5 , serum iPTH &gt; 150 pg/mL , Cardiac disease describe Medical Dictionary Regulatory Activities ( MedDRA ) term : cardiac disorder cardiac arrhythmia cardiac disorder sign symptom cardiac neoplasm cardiac valve disorder heart failures myocardial disorder pericardial disorder Serum phosphate level &lt; 6.5 mg/dL serum calcium level &lt; 10.5 mg/dL Patients meet contraindication outline late version Zemplar ( Paricalcitol IV ) summary product characteristic Patients know hypersensitivity paricalcitol component formulation , vitamin D intoxication , hypercalcemia ; cinacalcet concomitant medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Secondary Hyperparathyroidism ( sHPT )</keyword>
	<keyword>Paricalcitol</keyword>
	<keyword>Chronic kidney disease stage 5 ( CKD stage 5 )</keyword>
</DOC>